Should you still recommend omega-3 supplements?

Probably not. A new meta-analysis adds to a growing body of evidence that omega-3 fatty acids do little to protect against heart disease.

PRACTICE CHANGER
Stop recommending omega-3 fatty acid supplements for cardiovascular protection. They have no significant impact on all-cause mortality, acute myocardial infarction, sudden death, or stroke.1

STRENGTH OF RECOMMENDATION
A: Based on a meta-analysis of randomized controlled trials (RCTs).


ILLUSTRATIVE CASE
A 59-year-old patient who had a myocardial infarction (MI) 3 years ago is taking an ACE inhibitor, a statin, and a β-blocker. He asks you whether he should also take omega-3 fatty acid supplements to further decrease his risk of heart disease. What should you tell him?

Coronary artery disease (CAD) kills more than 500,000 Americans every year,2 and medical and dietary therapies for primary and secondary cardiovascular protection are paramount. Omega-3 polyunsaturated fatty acid (PUFA) supplementation is one such therapy. Omega-3 PUFAs are precursors to certain prostaglandins that decrease the proinflammatory state in patients with CAD. They also lower triglyceride levels and produce an antiarrhythmic effect by promoting electrical stability.

But do PUFA supplements provide cardioprotection?
The American Heart Association’s Nutrition Committee recommends either omega-3 PUFA supplementation with 250 to 500 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) per day or 2 servings of oily fish per week for both primary and secondary prevention of CAD.3 The European Society of Cardiology also encourages increased consumption of oily fish.4

These recommendations are based on primary and secondary prevention studies, performed between 1989 and 2007, that found a 15% to 29% decrease in all-cause mortality and nonfatal cardiovascular events associated with regular intake of omega-3 fatty acids.5-7 The systematic review and meta-analysis detailed below revisited the effect of omega-3 supplementation on major cardiovascular outcomes.1

STUDY SUMMARY
Omega-3 supplements don’t lower cardiovascular risk
This meta-analysis included 20 RCTs with a total of 68,680 patients. The median age was 68 years, with a range from 49 to 70 years. Thirteen of the studies evaluated omega-3 PUFAs for secondary prevention of cardiovascular outcomes, 4 assessed both primary and secondary prevention, and 3 looked at outcomes in patients with implantable cardioverter defibrillators. All lasted longer than
one year, and most were high quality, with a low risk of bias.

The median treatment duration was 2 years, with a maximum of 6.2 years. The mean omega-3 PUFA dose evaluated in the studies was 1.5 g per day, with the exception of 2 studies in which patients received omega-3 PUFAs through dietary sources. Twelve studies used a dose of 1 g or more per day. Half of the included trials were performed during the period when statins were routinely prescribed for cardiovascular risk modification (1998 or later).

Outcomes included all-cause mortality (17 studies), cardiac death (13 studies), sudden death (7 studies), MI (13 studies), and stroke (9 studies).

This meta-analysis found trends toward a decrease in all-cause mortality, cardiac death, sudden death, and MI in patients taking omega-3 PUFAs, but no statistically significant association between any of the outcomes and omega-3 PUFA supplementation. The relative risk for all-cause mortality was 0.96 (95% confidence interval, 0.91-1.02; \( P = .17 \)). Prespecified subgroup analysis found no association between treatment effect and omega-3 fatty acid dose.

**Are dietary sources of omega-3s more effective?**

In the 2 trials involving dietary supplementation with omega-3 PUFAs, the results for all-cause mortality and cardiac death were conflicting, with one showing an increase in all-cause mortality and cardiac death and the other showing a decrease in both outcomes compared with the control group.

No harmful effects of omega-3 PUFAs were found in either the supplement- or diet-based studies.

**CAVEATS**

No significant help, and no harm

While this meta-analysis found no statistically significant benefits from omega-3 PUFAs, there is no evidence of harm from PUFA intake, whether from dietary sources or supplements. There is no need to tell patients who wish to take omega-3 supplements not to do so. But we should not promote their use for the sole purpose of cardiovascular disease prevention.

**CHALLENGES TO IMPLEMENTATION**

Changing minds won’t be easy

Despite recent findings indicating that omega-3 PUFAs provide little primary or secondary protection against cardiovascular events, advertising from supplement manufacturers may make it hard to change patients’ minds. Because diets and supplements containing these fatty acids do not cause apparent harm, patients and physicians may decide that a small potential benefit is worth the expense.
ACKNOWLEDGMENT
The PURLs Surveillance System was supported in part by Grant Number U18R024999 from the National Center for Research Resources, a Clinical Translational Science Award to the University of Chicago. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

Copyright © 2013. The Family Physicians Inquiries Network. All rights reserved.

References

If you’re a physician looking for a career that engages your heart, as well as your mind...

Join PeaceHealth
We value wellness and a positive work-life balance while offering our physicians competitive compensation, robust benefits, relocation and bonus; student loan repayment for those who qualify.

Featuring opportunities in:
- Family Medicine
- Family Medicine with OB
- Family Medicine Traditional

PeaceHealth is an EEO & Affirmative Action Employer.

For more information
Dorothy Reed, CMSR
(541) 868-3454
dreed@peacehealth.org
www.peacehealth.org

Work, live, play.
Oregon • Washington

PRACTICE OPPORTUNITIES